Neddylation Mediates Ventricular Chamber Maturation PNAS PLUS Through Repression of Hippo Signaling

Total Page:16

File Type:pdf, Size:1020Kb

Neddylation Mediates Ventricular Chamber Maturation PNAS PLUS Through Repression of Hippo Signaling Neddylation mediates ventricular chamber maturation PNAS PLUS through repression of Hippo signaling Jianqiu Zoua, Wenxia Maa, Jie Lia, Rodney Littlejohna, Hongyi Zhoub, Il-man Kima, David J. R. Fultona, Weiqin Chenb, Neal L. Weintrauba, Jiliang Zhouc, and Huabo Sua,c,d,1 aVascular Biology Center, Medical College of Georgia, Augusta University, Augusta, GA 30912; bDepartment of Physiology, Medical College of Georgia, Augusta University, Augusta, GA 30912; cDepartment of Pharmacology and Toxicology, Medical College of Georgia, Augusta University, Augusta, GA 30912; and dProtein Modification and Degradation Lab, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, Guangdong 510260, China Edited by Deepak Srivastava, Gladstone Institute of Cardiovascular Disease, San Francisco, CA, and accepted by Editorial Board Member Brenda A. Schulman March 23, 2018 (received for review November 7, 2017) During development, ventricular chamber maturation is a crucial maturation of the ventricular wall is regulated by a complex sig- step in the formation of a functionally competent postnatal heart. naling network comprised of growth factors, transcription factors, Defects in this process can lead to left ventricular noncompaction and epigenetic regulators (3, 4), such as NRG1/ERBB2 (8), cardiomyopathy and heart failure. However, molecular mecha- NOTCH (9, 10), TGFβ (11, 12), Smad7 (13), and HDAC1/2 (14). nisms underlying ventricular chamber development remain However, the importance of novel ubiquitin-like protein modifiers incompletely understood. Neddylation is a posttranslational mod- in this process has not been demonstrated. ification that attaches ubiquitin-like protein NEDD8 to protein tar- Neural precursor cell expressed, developmentally down-regulated gets via NEDD8-specific E1-E2-E3 enzymes. Here, we report that 8 (NEDD8) is a ubiquitin-like protein that shares a high degree of neddylation is temporally regulated in the heart and plays a key homology with ubiquitin (15). NEDD8 is evolutionarily highly role in cardiac development. Cardiomyocyte-specific knockout of conserved and ubiquitously expressed in all cell types (16). Conju- NAE1, a subunit of the E1 neddylation activating enzyme, signifi- gation of NEDD8 to protein targets, termed neddylation, is a cantly decreased neddylated proteins in the heart. Mice lacking process analogous to ubiquitination and requires NEDD8-specific NAE1 developed myocardial hypoplasia, ventricular noncompac- tion, and heart failure at late gestation, which led to perinatal E1, E2, and E3 enzymes (17, 18). The only identified NEDD8 E1 is lethality. NAE1 deletion resulted in dysregulation of cell cycle- a heterodimer of NAE1 (also known as APP-BP1) and UBA3, regulatory genes and blockade of cardiomyocyte proliferation in which together activate NEDD8 in an ATP-dependent manner. vivo and in vitro, which was accompanied by the accumulation of With the aid of a NEDD8 E2 (UBC12) enzyme and yet to be fully the Hippo kinases Mst1 and LATS1/2 and the inactivation of the defined E3 ligases, activated NEDD8 is covalently fused with the YAP pathway. Furthermore, reactivation of YAP signaling in NAE1- lysine residue of substrate proteins via its C-terminal glycine, which inactivated cardiomyocytes restored cell proliferation, and YAP- can result in the addition of one or more NEDD8 molecules. deficient hearts displayed a noncompaction phenotype, supporting Neddylation is reversibly regulated; substrate proteins conjugated an important role of Hippo-YAP signaling in NAE1-depleted hearts. with NEDD8 can be “deneddylated” by NEDD8-specific proteases, PHYSIOLOGY Mechanistically, we found that neddylation regulates Mst1 and such as the COP9 signalosome (CSN) and NEDP1 (also known as LATS2 degradation and that Cullin 7, a NEDD8 substrate, acts as SENP8) (19, 20). the ubiquitin ligase of Mst1 to enable YAP signaling and cardiomyo- cyte proliferation. Together, these findings demonstrate a role Significance for neddylation in heart development and, more specifically, in the maturation of ventricular chambers and also identify the Myocardium thickening at midgestation to late gestation is NEDD8 substrate Cullin 7 as a regulator of Hippo-YAP signaling. crucial for the formation of a functionally competent postnatal heart. However, posttranslational mechanisms regulating this NEDD8 | Hippo-YAP signaling | Cullin 7 | ventricular compaction | process remain unexplored. Here, we uncover a critical role for cardiomyopathy the ubiquitin-like protein NEDD8 in heart development. By targeting the E1 enzyme that mediates the conjugation of ardiac development consists of a series of highly regulated NEDD8 to protein targets, we show that NEDD8 modification is Cspatiotemporal morphogenic events (1, 2). The maturation essential for ventricular compaction and heart function. We of the cardiac chamber during late gestation is a crucial step further identify that the NEDD8 substrate Cullin 7 mediates the toward the generation of a functionally competent postnatal degradation of Hippo kinase Mst1, thereby enabling YAP sig- heart and involves the coordination of ventricular trabeculation naling, cardiomyocyte proliferation, and proper heart devel- and compaction (3, 4). In the initial stages of heart development, opment. These results reveal a posttranslational regulatory trabeculae (an endocardium-lined myocardial mesh) protrude mechanism in ventricular wall maturation and may provide and expand into the ventricular lumen to increase the myocardial mechanistic insights into the etiology of left ventricular surface area for oxygen and nutrient exchange. From late noncompaction cardiomyopathy. midgestation to the late fetal and neonatal stage, the compact myocardium grows quickly and fuses with the trabecular myo- Author contributions: I.K., D.J.R.F., W.C., N.L.W., J. Zhou, and H.S. designed research; J. Zou, W.M., J.L., R.L., H.Z., and H.S. performed research; W.C. and J. Zhou contrib- cardium to form a thicker, and eventually mature, compact uted new reagents/analytic tools; J. Zou, W.M., J.L., R.L., H.Z., J. Zhou, and H.S. ventricular wall. Defects in cardiac chamber maturation lead to analyzed data; and J. Zou and H.S. wrote the paper. congenital heart diseases, including left ventricular noncompaction The authors declare no conflict of interest. cardiomyopathy (LVNC), the third most commonly diagnosed This article is a PNAS Direct Submission. D.S. is a guest editor invited by the Editorial Board. cardiomyopathy (5, 6). LVNC is characterized by deep and exten- Published under the PNAS license. sive trabeculae in a thin ventricular wall, which can result in dilated 1To whom correspondence should be addressed. Email: [email protected]. cardiomyopathy, heart failure, thromboembolism, arrhythmia, and This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. sudden cardiac death (7). Emerging studies from genetic analysis of 1073/pnas.1719309115/-/DCSupplemental. LVNC patients and animal models of LVNC have suggested that Published online April 9, 2018. www.pnas.org/cgi/doi/10.1073/pnas.1719309115 PNAS | vol. 115 | no. 17 | E4101–E4110 Downloaded by guest on October 1, 2021 Neddylation controls diverse cellular processes, including tran- the role of neddylation in perinatal cardiac development in a cell scriptional regulation, cell cycle progression and differentiation, lineage-specific fashion, we generated a conditional NAE1flox/flox ribosome biogenesis, apoptosis, inflammatory responses, and allele by flanking exon 4 with loxP sites (SI Appendix, Fig. S2A). proteolysis, via altering the activity, stability, subcellular locali- Cardiomyocyte-restricted NAE1 knockout (NAE1CKO,NAE1flox/flox/ zation, and DNA binding affinity of conjugated proteins (17, 18). αMHCCre) mice were then created by crossing NAE1flox/flox Among the growing list of NEDD8 targets, the Cullin proteins mice with αMHC-driven Cre transgenic (αMHCCre)mice,in (Cullin 1 to 5, 7, and 9) are the best-characterized substrates. which Cre recombinase activity can be detected in the heart as Acting as scaffold proteins, Cullins recruit substrate recogni- early as E9.5 and is present in a majority of ventricular car- tion subunits and a RING domain protein to form functional diomyocytes at E13.5 (37, 38). PCR and quantitative real-time Cullin-RING ubiquitin ligases (CRLs) (21), which together PCR analyses confirmed the deletion of NAE1 in the NAE1CKO mediate the proteolysis of ∼20% of cellular proteins (22). hearts, compared with their littermate control hearts (CTLs) + Neddylation of Cullins induces the assembly of CRLs and thus is (NAE1flox/flox or NAE1flox/ )(SI Appendix, Fig. S2 B and C). essential for their ubiquitin ligase activity (21). Western blot analyses of whole heart lysates revealed ∼40% and Recent studies have begun to define the physiopathological ∼70% reduction of NAE1 proteins in NAE1CKO hearts at E12.5 significance of neddylation in embryonic development (23), and postnatal day (P) 1, respectively (SI Appendix, Fig. S2 D and synapse formation and maturation (24, 25), adipogenesis (26), E). The residual NAE1 mRNA and protein in the NAE1CKO tumor development (22), and, more recently, cardiac homeo- hearts are likely from noncardiomyocytes in which NAE1 gene stasis (27–30). Neddylation is dysregulated in the failing human was not deleted and/or NAE1 mRNA and protein that persist in heart and in multiple mouse models of cardiac disease (31). the cardiomyocytes at P1. Inactivation of deneddylation in mouse hearts
Recommended publications
  • Cell Cycle Arrest and DNA Endoreduplication Following P21waf1/Cip1 Expression
    Oncogene (1998) 17, 1691 ± 1703 1998 Stockton Press All rights reserved 0950 ± 9232/98 $12.00 http://www.stockton-press.co.uk/onc Cell cycle arrest and DNA endoreduplication following p21Waf1/Cip1 expression Stewart Bates, Kevin M Ryan, Andrew C Phillips and Karen H Vousden ABL Basic Research Program, NCI-FCRDC, Building 560, Room 22-96, West 7th Street, Frederick, Maryland 21702-1201, USA p21Waf1/Cip1 is a major transcriptional target of p53 and there are an increasing number of regulatory mechan- has been shown to be one of the principal mediators of isms that serve to inhibit cdk activity. Primary amongst the p53 induced G1 cell cycle arrest. We show that in these is the expression of cdk inhibitors (CDKIs) that addition to the G1 block, p21Waf1/Cip1 can also contribute can bind to and inhibit cyclin/cdk complexes (Sherr to a delay in G2 and expression of p21Waf1/Cip1 gives rise and Roberts, 1996). These fall into two classes, the to cell cycle pro®les essentially indistinguishable from INK family which bind to cdk4 and cdk6 and inhibit those obtained following p53 expression. Arrest of cells complex formation with D-cyclins, and the p21Waf1/Cip1 in G2 likely re¯ects an inability to induce cyclin B1/cdc2 family that bind to cyclin/cdk complexes and inhibit kinase activity in the presence of p21Waf1/Cip1, although the kinase activity. inecient association of p21Waf1/Cip1 and cyclin B1 The p21Waf1/Cip1 family of CDKIs include p21Waf1/Cip1, suggests that the mechanism of inhibition is indirect. p27 and p57 and are broad range inhibitors of cyclin/ Cells released from an S-phase block were not retarded cdk complexes (Gu et al., 1993; Harper et al., 1993; in their ability to progress through S-phase by the Xiong et al., 1993; Firpo et al., 1994; Polyak et al., presence of p21Waf1/Cip1, despite ecient inhibition of 1994; Toyoshima and Hunter, 1994; Lee et al., 1995; cyclin E, A and B1 dependent kinase activity, suggesting Matsuoka et al., 1995).
    [Show full text]
  • CDKN2A and CDKN2B Methylation in Coronary Heart Disease Cases and Controls
    EXPERIMENTAL AND THERAPEUTIC MEDICINE 14: 6093-6098, 2016 CDKN2A and CDKN2B methylation in coronary heart disease cases and controls JINYAN ZHONG1,2*, XIAOYING CHEN3*, HUADAN YE3, NAN WU1,3, XIAOMIN CHEN1 and SHIWEI DUAN3 1Cardiology Center, Ningbo First Hospital, Ningbo University; 2Department of Cardiology, Ningbo Second Hospital, Ningbo, Zhejiang 315010; 3Medical Genetics Center, School of Medicine, Ningbo University, Ningbo, Zhejiang 315211, P.R. China Received May 27, 2016; Accepted March 24, 2017 DOI: 10.3892/etm.2017.5310 Abstract. The aim of the present study was to investigate frequencies were significantly associated with age, and there the association between cyclin-dependent kinase inhibitor was a gender dimorphism in CDKN2B methylation. 2A (CDKN2A) and cyclin-dependent kinase inhibitor 2B (CDKN2B) methylation, and coronary heart disease (CHD), Introduction and to explore the interaction between methylation status and CHD clinical characteristics in Han Chinese patients. A total Coronary heart disease (CHD) is a complex chronic disease of 189 CHD (96 males, 93 females) and 190 well-matched that is caused by an imbalance between blood supply and non-CHD controls (96 males, 94 females) were recruited for demand in myocardium. Various environmental and genetic the study. Methylation-specific polymerase chain reaction factors are known to contribute to onset and development of technology was used to examine gene promoter methylation CHD (1). As of 2010, CHD was the leading cause of mortality status. Comparisons of methylation frequencies between CHD globally, resulting in over 7 million cases of mortality (2). and non-CHD patients were carried out using the Chi-square Therefore, association studies for CHD biomarkers have been test.
    [Show full text]
  • Epigenetic Silencing of CDKN1A and CDKN2B by SNHG1 Promotes The
    Li et al. Cell Death and Disease (2020) 11:823 https://doi.org/10.1038/s41419-020-03031-6 Cell Death & Disease ARTICLE Open Access Epigenetic silencing of CDKN1A and CDKN2B by SNHG1 promotes the cell cycle, migration and epithelial-mesenchymal transition progression of hepatocellular carcinoma Bei Li1,AngLi2, Zhen You 1,JingchangXu1 and Sha Zhu3 Abstract Enhanced SNHG1 (small nucleolar RNA host gene 1) expression has been found to play a critical role in the initiation and progression of hepatocellular carcinoma (HCC) with its detailed mechanism largely unknown. In this study, we show that SNHG1 promotes the HCC progression through epigenetically silencing CDKN1A and CDKN2B in the nucleus, and competing with CDK4 mRNA for binding miR-140-5p in the cytoplasm. Using bioinformatics analyses, we found hepatocarcinogenesis is particularly associated with dysregulated expression of SNHG1 and activation of the cell cycle pathway. SNHG1 was upregulated in HCC tissues and cells, and its knockdown significantly inhibited HCC cell cycle, growth, metastasis, and epithelial–mesenchymal transition (EMT) both in vitro and in vivo. Chromatin immunoprecipitation and RNA immunoprecipitation assays demonstrate that SNHG1 inhibit the transcription of CDKN1A and CDKN2B through enhancing EZH2 mediated-H3K27me3 in the promoter of CDKN1A and CDKN2B, thus resulting in the de-repression of the cell cycle. Dual-luciferase assay and RNA pulldown revealed that SNHG1 promotes 1234567890():,; 1234567890():,; 1234567890():,; 1234567890():,; the expression of CDK4 by competitively binding to miR-140-5p. In conclusion, we propose that SNHG1 formed a regulatory network to confer an oncogenic function in HCC and SNHG1 may serve as a potential target for HCC diagnosis and treatment.
    [Show full text]
  • Infrequent Methylation of CDKN2A(Mts1p16) and Rare Mutation of Both CDKN2A and CDKN2B(Mts2ip15) in Primary Astrocytic Tumours
    British Joumal of Cancer (1997) 75(1), 2-8 © 1997 Cancer Research Campaign Infrequent methylation of CDKN2A(MTS1p16) and rare mutation of both CDKN2A and CDKN2B(MTS2Ip15) in primary astrocytic tumours EE Schmidt, K Ichimura, KR Messerle, HM Goike and VP Collins Institute for Oncology and Pathology, Division of Tumour Pathology, and Ludwig Institute for Cancer Research, Stockholm Branch, Karolinska Hospital, S-171 76 Stockholm, Sweden Summary In a series of 46 glioblastomas, 16 anaplastic astrocytomas and eight astrocytomas, all tumours retaining one or both alleles of CDKN2A (48 tumours) and CDKN2B (49 tumours) were subjected to sequence analysis (entire coding region and splice acceptor and donor sites). One glioblastoma with hemizygous deletion of CDKN2A showed a missense mutation in exon 2 (codon 83) that would result in the substitution of tyrosine for histidine in the protein. None of the tumours retaining alleles of CDKN2B showed mutations of this gene. Glioblastomas with retention of both alleles of CDKN2A (14 tumours) and CDKN2B (16 tumours) expressed transcripts for these genes. In contrast, 7/13 glioblastomas with hemizygous deletions of CDKN2A and 8/11 glioblastomas with hemizygous deletions of CDKN2B showed no or weak expression. Anaplastic astrocytomas and astrocytomas showed a considerable variation in the expression of both genes, regardless of whether they retained one or two copies of the genes. The methylation status of the 5' CpG island of the CDKN2A gene was studied in all 15 tumours retaining only one allele of CDKN2A as well as in the six tumours showing no significant expression of transcript despite their retaining both CDKN2A alleles.
    [Show full text]
  • The Expression of P21/WAF-1 and Cyclin B1 Mediate Mitotic Delay in X-Irradiated Fibroblasts
    ANTICANCER RESEARCH 25: 1123-1130 (2005) The Expression of p21/WAF-1 and Cyclin B1 Mediate Mitotic Delay in x-Irradiated Fibroblasts MICKAEL J. CARIVEAU1,2, CHARLES J. KOVACS2, RON R. ALLISON2, ROBERTA M. JOHNKE2, GERHARD W. KALMUS3 and MARK EVANS2 1Department of Physics, East Carolina University, Greenville NC, 27858; 2Department of Radiation Oncology, The Brody School of Medicine, East Carolina University, Greenville NC, 27858; 3Department of Biology, East Carolina University, Greenville NC, 27858, U.S.A. Abstract. Background: To better understand the relationship Initiation and maintenance of cell cycle arrest is regulated between mitotic delay and the disruption of cyclin B1 and p21 in by a group of proteins known as the cyclins which function x-irradiated fibroblasts, studies were carried out to establish by coupling to their corresponding cyclin dependent kinases correlations between the downregulation of cyclin B1 by the cyclin (CDK) (6-9). Of particular interest to cell cycle arrest in kinase inhibitor (CKI) p21 and the induction of mitotic delay in response to DNA damage is the G2/M damage checkpoint the NIH3T3 fibroblast. Materials and Methods: Cell cycle kinetics which is regulated by cyclin B1/CDK1 and initiated by DNA were used to analyze mitotic delay in irradiated NIH3T3 cells and damage activation of the cyclin kinase inhibitor p21(10-14). immunocytochemistry incorporated to assess the expression of The inhibitory potential of p21 is well established; however, cyclin B1 and p21, following 2 or 4Gy x-irradiation. Results and there is still much confusion about the role of p21 in the Discussion: Results indicate a dose dependent increase in mitotic irradiated cell (15, 16).
    [Show full text]
  • A Variant at 9P21.3 Functionally Implicates CDKN2B in Paediatric B-Cell Precursor Acute Lymphoblastic Leukaemia Aetiology
    UCSF UC San Francisco Previously Published Works Title A variant at 9p21.3 functionally implicates CDKN2B in paediatric B-cell precursor acute lymphoblastic leukaemia aetiology. Permalink https://escholarship.org/uc/item/3bz9m1pp Journal Nature communications, 7(1) ISSN 2041-1723 Authors Hungate, Eric A Vora, Sapana R Gamazon, Eric R et al. Publication Date 2016-02-12 DOI 10.1038/ncomms10635 Peer reviewed eScholarship.org Powered by the California Digital Library University of California ARTICLE Received 23 Apr 2015 | Accepted 7 Jan 2016 | Published 12 Feb 2016 DOI: 10.1038/ncomms10635 OPEN A variant at 9p21.3 functionally implicates CDKN2B in paediatric B-cell precursor acute lymphoblastic leukaemia aetiology Eric A. Hungate1,*, Sapana R. Vora2,*, Eric R. Gamazon3,4, Takaya Moriyama5, Timothy Best2, Imge Hulur6, Younghee Lee3, Tiffany-Jane Evans7, Eva Ellinghaus8, Martin Stanulla9,Je´remie Rudant10,11, Laurent Orsi10,11, Jacqueline Clavel10,11,12, Elizabeth Milne13, Rodney J. Scott7,14, Ching-Hon Pui15, Nancy J. Cox3, Mignon L. Loh16, Jun J. Yang5, Andrew D. Skol1 & Kenan Onel1 Paediatric B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) is the most common cancer of childhood, yet little is known about BCP-ALL predisposition. In this study, in 2,187 cases of European ancestry and 5,543 controls, we discover and replicate a locus indexed by À 15 rs77728904 at 9p21.3 associated with BCP-ALL susceptibility (Pcombined ¼ 3.32 Â 10 , OR ¼ 1.72) and independent from rs3731217, the previously reported ALL-associated variant in this region. Of correlated SNPs tagged by this locus, only rs662463 is significant in African Americans, suggesting it is a plausible causative variant.
    [Show full text]
  • Supplemental Table S1 (A): Microarray Datasets Characteristics
    Supplemental table S1 (A): Microarray datasets characteristics Title Summary Samples Literature ref. GEO ref. Acquisition of granule Gene expression profiling of 27 (1) GSE 11859 neuron precursor identity cerebellar tumors generated and Hedgehog‐induced from various early and late medulloblastoma in mice. stage CNS progenitor cells Medulloblastomas derived Study of mouse 5 (2) GSE 7212 from Cxcr6 mutant mice medulloblastoma in response respond to treatment with to inhibitor of Smoothened a Smoothened inhibitor Expression profiles of Identification of distinct classes 10 (3) GSE 9299 mouse medulloblastoma of up‐regulated or down‐ 339 & 340 regulated genes during Hh dependent tumorigenesis Genetic alterations in Identification of differently 10 (4) GSE 6463 mouse medulloblastomas expressed genes among CGNPs 339 & and generation of tumors and CGNPs transfected with 340 from cerebellar granule retroviruses that express nmyc neuron precursors or cyclin‐d1 Patched heterozygous Analysis of granule cell 14 (5) GSE 2426 model of medulloblastoma precursors, pre‐neoplastic cells, GDS1110 and tumor cells 1. Schuller U, Heine VM, Mao J, Kho AT, Dillon AK, Han YG, et al. Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh‐induced medulloblastoma. Cancer Cell 2008;14:123‐134. 2. Sasai K, Romer JT, Kimura H, Eberhart DE, Rice DS, Curran T. Medulloblastomas derived from Cxcr6 mutant mice respond to treatment with a smoothened inhibitor. Cancer Res 2007;67:3871‐3877. 3. Mao J, Ligon KL, Rakhlin EY, Thayer SP, Bronson RT, Rowitch D, et al. A novel somatic mouse model to survey tumorigenic potential applied to the Hedgehog pathway. Cancer Res 2006;66:10171‐10178.
    [Show full text]
  • Deregulation of the P14arf/MDM2/P53 Pathway Is A
    [CANCER RESEARCH 60, 417–424, January 15, 2000] Deregulation of the p14ARF/MDM2/p53 Pathway Is a Prerequisite for Human 1 Astrocytic Gliomas with G1-S Transition Control Gene Abnormalities Koichi Ichimura, Maria Bondesson Bolin,2 Helena M. Goike, Esther E. Schmidt, Ahmad Moshref, and V. Peter Collins3 Department of Pathology, Division of Molecular Histopathology, University of Cambridge, Addenbrooke’s Hospital, Cambridge CB2 2QQ, United Kingdom [K. I., E. E. S., V. P. C], and Ludwig Institute for Cancer Research and Unit of Tumorpathology, Department of Oncology and Pathology, Karolinska Hospital, 171 76 Stockholm, Sweden [K. I., M. B. B., H. M. G., E. E. S., A. M., V. P. C.] ABSTRACT There are several lines of evidence to indicate that deregulation of G1-S transition control alone may be detrimental for cell survival: (a) Deregulation of G -S transition control in cell cycle is one of the 1 transfection of rodent cells with the adenoviral E1A and E1B genes important mechanisms in the development of human tumors including resulted in transformation due to the viral proteins binding to and astrocytic gliomas. We have previously reported that approximately two- inactivating pRB and p53. Transfection with E1A alone induced p53 thirds of glioblastomas (GBs) had abnormalities of G1-S transition control either by mutation/homozygous deletion of RB1 or CDKN2A (p16INK4A), dependent apoptosis (10); (b) when E2F1 was ectopically expressed in or amplification of CDK4 (K. Ichimura et al., Oncogene, 13: 1065–1072, rodent embryo fibroblasts, although the cell indeed entered S phase 1996). However, abnormalities of G1-S transition control genes may in- (11), apoptosis was induced in a p53-dependent manner (12); (c) loss duce p53-dependent apoptosis in cells.
    [Show full text]
  • Role of Cyclin-Dependent Kinase 1 in Translational Regulation in the M-Phase
    cells Review Role of Cyclin-Dependent Kinase 1 in Translational Regulation in the M-Phase Jaroslav Kalous *, Denisa Jansová and Andrej Šušor Institute of Animal Physiology and Genetics, Academy of Sciences of the Czech Republic, Rumburska 89, 27721 Libechov, Czech Republic; [email protected] (D.J.); [email protected] (A.Š.) * Correspondence: [email protected] Received: 28 April 2020; Accepted: 24 June 2020; Published: 27 June 2020 Abstract: Cyclin dependent kinase 1 (CDK1) has been primarily identified as a key cell cycle regulator in both mitosis and meiosis. Recently, an extramitotic function of CDK1 emerged when evidence was found that CDK1 is involved in many cellular events that are essential for cell proliferation and survival. In this review we summarize the involvement of CDK1 in the initiation and elongation steps of protein synthesis in the cell. During its activation, CDK1 influences the initiation of protein synthesis, promotes the activity of specific translational initiation factors and affects the functioning of a subset of elongation factors. Our review provides insights into gene expression regulation during the transcriptionally silent M-phase and describes quantitative and qualitative translational changes based on the extramitotic role of the cell cycle master regulator CDK1 to optimize temporal synthesis of proteins to sustain the division-related processes: mitosis and cytokinesis. Keywords: CDK1; 4E-BP1; mTOR; mRNA; translation; M-phase 1. Introduction 1.1. Cyclin Dependent Kinase 1 (CDK1) Is a Subunit of the M Phase-Promoting Factor (MPF) CDK1, a serine/threonine kinase, is a catalytic subunit of the M phase-promoting factor (MPF) complex which is essential for cell cycle control during the G1-S and G2-M phase transitions of eukaryotic cells.
    [Show full text]
  • Regulation of P27kip1 and P57kip2 Functions by Natural Polyphenols
    biomolecules Review Regulation of p27Kip1 and p57Kip2 Functions by Natural Polyphenols Gian Luigi Russo 1,* , Emanuela Stampone 2 , Carmen Cervellera 1 and Adriana Borriello 2,* 1 National Research Council, Institute of Food Sciences, 83100 Avellino, Italy; [email protected] 2 Department of Precision Medicine, University of Campania “Luigi Vanvitelli”, 81031 Napoli, Italy; [email protected] * Correspondence: [email protected] (G.L.R.); [email protected] (A.B.); Tel.: +39-0825-299-331 (G.L.R.) Received: 31 July 2020; Accepted: 9 September 2020; Published: 13 September 2020 Abstract: In numerous instances, the fate of a single cell not only represents its peculiar outcome but also contributes to the overall status of an organism. In turn, the cell division cycle and its control strongly influence cell destiny, playing a critical role in targeting it towards a specific phenotype. Several factors participate in the control of growth, and among them, p27Kip1 and p57Kip2, two proteins modulating various transitions of the cell cycle, appear to play key functions. In this review, the major features of p27 and p57 will be described, focusing, in particular, on their recently identified roles not directly correlated with cell cycle modulation. Then, their possible roles as molecular effectors of polyphenols’ activities will be discussed. Polyphenols represent a large family of natural bioactive molecules that have been demonstrated to exhibit promising protective activities against several human diseases. Their use has also been proposed in association with classical therapies for improving their clinical effects and for diminishing their negative side activities. The importance of p27Kip1 and p57Kip2 in polyphenols’ cellular effects will be discussed with the aim of identifying novel therapeutic strategies for the treatment of important human diseases, such as cancers, characterized by an altered control of growth.
    [Show full text]
  • Prostate Cancer Cell Proliferation Is Suppressed by Microrna‑3160‑5P Via Targeting of F‑Box and WD Repeat Domain Containing 8
    9436 ONCOLOGY LETTERS 15: 9436-9442, 2018 Prostate cancer cell proliferation is suppressed by microRNA‑3160‑5p via targeting of F‑box and WD repeat domain containing 8 PING LIN1*, LIJUAN ZHU1*, WENJING SUN1, ZHENGKAI YANG1, HUI SUN1, DONG LI1, RONGJUN CUI1,2, XIULAN ZHENG1,3 and XIAOGUANG YU1 1Department of Biochemistry and Molecular Biology, Harbin Medical University, Harbin, Heilongjiang 150081; 2Department of Biochemistry and Molecular Biology, Mudanjiang Medical University, Mudanjiang, Heilongjiang 157011; 3Department of Ultrasonography and Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150081, P.R. China Received January 19, 2016; Accepted December 15, 2017 DOI: 10.3892/ol.2018.8505 Abstract. MicroRNAs (miRNAs/miRs), which are endog- Introduction enous non-coding single-stranded RNAs 19-25 nucleotides in length, regulate gene expression by blocking translation Prostate cancer (PCa) is the most frequently diagnosed cancer or transcription repression. The present study revealed that in males. Furthermore, PCa is the second leading cause of miR-3160-5p was widely expressed in prostate cancer cells by cancer-associated mortality in males in the USA and there reverse transcription-quantitative polymerase chain reaction. were 220,800 reported cases of PCa in the USA in 2015 (1). There was a negative association between the expression of Additionally, the mortality and incidence rates of PCa have miR-3160-5p and F-box and WD repeat domain containing increased rapidly in China (2). Surgery and radiotherapy are 8 (Fbxw8) in prostate cancer DU145 cells. A luciferase successful treatments for early and localized tumors (3,4), but activity assay was used to verify that Fbxw8 is the target of the preferred therapy for advanced PCa is androgen-depri- miR-3160-5p.
    [Show full text]
  • Cyclin E1 and Rb Modulation As Common Events at Time of Resistance to Palbociclib in Hormone Receptor-Positive Breast Cancer
    www.nature.com/npjbcancer ARTICLE OPEN Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer Cristina Guarducci1, Martina Bonechi1, Matteo Benelli2, Chiara Biagioni2,3, Giulia Boccalini1, Dario Romagnoli2, Roberto Verardo4, Rachel Schiff5,6,7,8, C. Kent Osborne5,6,7,8, Carmine De Angelis5,6,8, Angelo Di Leo3, Luca Malorni1,3 and Ilenia Migliaccio1 CDK4/6 inhibitors represent a new treatment standard for hormone receptor-positive (HR+), HER2-negative advanced breast cancer (BC) patients. Although efficacious, resistance to these agents is universal. Here, we profiled a large panel of HR+ BC cell lines with conditioned resistance to the CDK4/6 inhibitor palbociclib, and analyzed cell cycle-related markers by gene expression profiles (GEP) and western blot (WB). GEP showed high molecular heterogeneity among the models, with E2F targets being significantly enriched both during treatment and at the time of resistance. By both WB and GEP, a common molecular feature at the time of palbociclib resistance was the concomitant overexpression of cyclin E1 and down-regulation of Rb. CCNE1 was the only significantly up-regulated gene among E2F targets at resistance with CCNE1 genomic amplification being observed in two resistant models. Rb was downregulated in all resistant models; a reduction of RB1 copy number was observed in three resistant cell lines. In silico analyses showed that CCNE1/RB1 ratio correlated with palbociclib IC50 in different datasets of both breast and non-breast cancer cell lines, performing better than CCNE1 or RB1 taken separately. Finally, the CCNE1/RB1 ratio was shown to be an adverse prognostic factor in patients with ER+ BC and to be able to discriminate palbociclib-sensitive versus resistant among patients enrolled in the NeoPalAna trial, a neoadjuvant trial testing palbociclib, performing better than CCNE1 or RB1 alone.
    [Show full text]